OMNIPRED Drug Patent Profile
✉ Email this page to a colleague
When do Omnipred patents expire, and when can generic versions of Omnipred launch?
Omnipred is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in OMNIPRED is prednisolone acetate. There are eighty-eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the prednisolone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNIPRED?
- What are the global sales for OMNIPRED?
- What is Average Wholesale Price for OMNIPRED?
Summary for OMNIPRED
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 74 |
Clinical Trials: | 3 |
Patent Applications: | 4,099 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in OMNIPRED? | OMNIPRED excipients list |
DailyMed Link: | OMNIPRED at DailyMed |
![OMNIPRED drug patent expirations Drug patent expirations by year for OMNIPRED](/p/graph/s/t/OMNIPRED-patent-expirations.png)
Recent Clinical Trials for OMNIPRED
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Winston Chamberlain, MD, PhD | Phase 4 |
Stanford University | Phase 4 |
Oregon Health and Science University | Phase 4 |
US Patents and Regulatory Information for OMNIPRED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | OMNIPRED | prednisolone acetate | SUSPENSION/DROPS;OPHTHALMIC | 017469-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |